HAIFA, Israel, May 7, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that it has identified its first clinical indication in the hematology field for its Placental eXpanded (PLX) RAD cells for the enhancement of the engraftment of Hematopoietic Stem Cells (HSC) in patients experiencing a delay or failure of their bone marrow transplant (BMT). This follows Pluristem's completion of additional pre-clinical studies showing promising results for PLX-RAD for this indication.
According to the National Marrow Donor Program, an estimated 25,000 allogeneic bone marrow transplants are performed annually worldwide. Approximately 15% of these patients will either have a delay or failure to engraft the HSCs, resulting in a condition that is life threatening, expensive and often requires the continued support of the patient with blood products. PLX-RAD may be beneficial to these patients.
PLX-RAD is currently being evaluated by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health, in models of the acute radiation syndrome (ARS).PLX-RAD, Pluristem's second product candidate, joins PLX-PAD that is in clinical trials for the treatment of peripheral artery disease, muscle injury and Pulmonary Hypertension. Both product candidates are derived from placental raw material. The placenta is a very rich source for a variety of cells and Pluristem differentiates these products through the use of different cell populations combined with its proprietary 3D bioreactor manufacturing process that allows the company to change but precisely control the environment in which the cells grow. This results in a stable, consistent change to the therapeutic protein secretion profile of the cell that constitutes the difference between PLX-PAD and PLX-RAD. Pluristem intends to develop additional PLX products by capitalizing on these unique competitive advantages.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV